Pressure BioScience (OTCQB: PBIO), a leader in the
development and sale of broadly enabling, pressure-based instruments,
consumables and platform-technology solutions to the worldwide life sciences
and other industries, today announced that the combination of PBIO’s patented
Pressure Cycling Technology (“PCT”) with RedShiftBio’s proprietary Microfluidic
Modulation Spectroscopy (“MMS”) has resulted in a powerful new platform for
biotherapeutic drug development (“PCT-enhanced MMS”). PBIO believes combining
both platforms enables for the rigorous investigation of protein structure and
stability in a highly efficient workflow that can be crucial in drug
development. Per the release, the collaboration should result in faster
development of new drugs as well as improvement in the quality of drugs coming
onto the market. “Our collaboration with RedShiftBio takes advantage of our
ability to manipulate protein structure with high pressure and RedShiftBio’s
precise analytical platform that reports subtle changes in the
three-dimensional structure of protein molecules that could lead to protein
aggregation. Unfortunately, aggregated protein biologics could train a
patient’s immune system to recognize and eliminate the drug, so finding
appropriate formulations to prevent aggregation is a major task in
biopharmaceutical drug development. Moreover, MMS will help us to understand
protein folding kinetics in our BaroFold platform, which uses high pressure to
shape recombinant proteins into their active and stable conformations in
biomanufacturing process development,” Alexander V. Lazarev, Ph.D., Chief
Science Officer of PBIO stated in the news release.
To view the full press release, visit http://ibn.fm/rvqFS
About Pressure BioSciences Inc.
Pressure BioSciences is a leader in the development and sale
of innovative, broadly enabling, pressure-based solutions for the worldwide
life-sciences industry. The company’s products are based on the unique
properties of both constant (i.e., static) and alternating (i.e.,
pressure-cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented,
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil and plant biology, forensics and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired, patented technology from BaroFold
Inc. (the “BaroFold” technology) to allow entry into the biopharma contract
services sector, and (2) the use of its recently patented, scalable,
high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i)
create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and
water) and (ii) prepare higher-quality, homogenized, extended shelf-life or
room-temperature, stable, low-acid liquid foods that cannot be effectively
preserved using existing nonthermal technologies. For more information, visit
the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
